Medscape Medical NewsAll articles

DeepCT

Deep01 Limited • Radiology • 07/10/2019

510(k)IEC 62304 Class B
FDA Summary PDF

Device Purpose

DeepCT is an artificial intelligence-driven software designed to expedite the identification of suspected intracranial hemorrhage in non-contrast head CT scans by providing rapid notifications to specialists. Utilizing a deep residual convolutional neural network (ResNet) trained on extensive radiological data, the system analyzes DICOM images to improve triage efficiency in acute care settings without replacing definitive diagnostic procedures or full patient evaluation.

Summary

DeepCT is a software-only medical device designed to assist clinicians in hospital emergency rooms by rapidly identifying potential cases of intracranial hemorrhage (ICH) from non-contrast CT brain scans. It functions as a notification-only tool, operating in parallel with standard care workflows to flag images for specialist review. The system comprises two main components: an Image Forwarding Software that transmits DICOM images and displays notifications, and an Image Processing and Analysis Server that houses the core artificial intelligence algorithm. This server receives, processes, and analyzes the CT images, sending results back to the forwarding software, and is intended for use by trained clinicians within hospital networks to identify and communicate images of specific patients to a specialist, independent of the standard care workflow. The core technology of DeepCT is a 34-layer deep residual convolutional neural network (ResNet), trained using the PyTorch library on a large dataset of over 21,000 retrospective head CT scans collected between 2007 and 2017. This AI model is specifically engineered to detect image characteristics consistent with ICH by analyzing non-contrast CT images of the brain acquired in acute settings. Performance validation was conducted through a retrospective, multicenter, multinational study involving 260 cases from five clinical sites, demonstrating a sensitivity of 93.8% and a specificity of 92.3% in identifying ICH, both exceeding the 80% performance goal. The average image processing and notification time was approximately 30.6 seconds, highlighting its capability for rapid triage support, though it is not intended for diagnostic use beyond notification and should not replace full patient evaluation.

AI Regulatory Concerns

Powered byJev by TypeSafe AI

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

Keywords

DeepCTIntracranial Hemorrhage (ICH)Artificial Intelligence (AI)Computed Tomography (CT)Radiological TriageNotification SoftwareDeep LearningResNetDICOMNon-contrast CT

Device Metadata

Submission Number
K182875
Company
Deep01 Limited
Panel
Radiology
Product Code
N/A
Data Type
Images
Clinical Function
Assessment
AI Function
Analysis
AI Subclass
triage

Relevant Clinical Questions

  • Q1. How does the DeepCT algorithm differentiate between different types or severities of intracranial hemorrhage (e.g., subdural, epidural, subarachnoid, intraparenchymal)?; What were the specific inclusion/exclusion criteria for the 21,603 patient CT scans used in the training dataset, and how might biases in this dataset affect real-world performance across diverse populations?; Beyond sensitivity and specificity, what is the positive predictive value (PPV) and negative predictive value (NPV) of DeepCT in a typical emergency department setting with varying ICH prevalence rates?; How does the system handle images with significant artifacts or poor image quality, and what is the failure rate or an "unable to analyze" output under such conditions?; What specific IT infrastructure and security protocols are required for the seamless and secure integration of DeepCT's Image Forwarding Software and Image Processing and Analysis Server within a hospital's existing network and PACS?

Risk Classification

ESL Analysis
FDA Device ClassII

FDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement

Learn how Parasoft automates IEC 62304 compliance testing →

Cybersecurity Evidence

Powered by SBOMator™

Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.

Cyber Score45/100
SBOM Evidence⚠ Not mentioned in summary
Cyber Risk Assessment✓ Detected in Summary
Postmarket Plan✓ Detected in Summary
§524B ApplicableNo

Supply Chain BOM Evidence

Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.

SBOMSoftware Bill of Materials
- Not detected
ML-BOMMachine Learning Bill of Materials(training data, deep learning, neural network, algorithm, dataset)
✓ Detected
SaaSBOMSoftware-as-a-Service Bill of Materials(server, network, infrastructure)
✓ Detected
HBOMHardware Bill of Materials
- Not detected
CBOMCryptography Bill of Materials
- Not detected
VDR/VEXVulnerability Disclosure Report / Vulnerability Exploitability eXchange
- Not detected
OBOMOperations Bill of Materials
- Not detected

Analysis:

• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.

• Evidence of ML-BOM, SaaSBOM detected in AI-generated device summary.

• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.

• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.

Preparing a similar submission?

ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.

Assess Your Readiness →Or contact ESL directly
DeepCT - Deep01 Limited | ESL FDA AI Device Intelligence